Skip to main content
. 2019 Aug 2;11(8):384. doi: 10.3390/pharmaceutics11080384

Figure 5.

Figure 5

Viability of BC cells treated with Eve or HEve nanoparticles. BT474, SKBR3, MDA-MB 231, and MCF-7 cells were treated with 1, 10, 50, and 100 nM Eve or HEve for 72 h. Viability was assessed by measuring the conversion of MTS into formazan. Reported values are the mean of six replicates ± s.e., normalized to cell proliferation of untreated cells. Statistical significance of HEve vs. free drug, * p < 0.05; ** p < 0.005; *** p < 0.0005 (Student’s t-test).